FDA-Approved Indication(s)

• Indicated for 1) Metastatic colorectal cancer, with a) intravenous 5-fluorouracil_based chemotherapy for first- or second-line treatment, or b) fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line Avastin containing regimen; Ê2) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease; 3) Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy; 4) Metastatic renal cell carcinoma with interferon alfa; Ê5) Cervical cancer, in combination with paclitaxel and cisplatin or topotecan in persistent, recurrent, or metastatic disease, 6) Epithelial ovarian, fallopian tube, or primary peritoneal cancer, a) in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for Stage III or IV disease following initial surgical resection, b) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for platinum resistant disease who have received no more than 2 prior chemotherapy regimens, or c) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum sensitive recurrent disease; and 7) Hepatocellular carcinoma (HCC), in combination with atezolizumab, for the treatment of patientsÊwith unresectable or metastatic HCC who have not received prior systemic therapy. (8/25/20)Ê